Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17786764 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17601605 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17432750 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | Non-Final OA | New York University |
| 17585286 | Inhibitors of Multidrug Resistance Transporter P-Glycoprotein | Non-Final OA | Southern Methodist University |
| 17631125 | COLLAGEN PRODUCTION PROMOTER, WRINKLE IMPROVER, TOPICAL SKIN CARE COMPOSITION, AND BEAUTY FOOD OR BEVERAGE | Final Rejection | REFINE HOLDINGS CO., LTD. |
| 18576973 | OXAFURAMINE, (1R)-N-ETHYL-1-[(2R)-OXOLAN-2-YL]-2-PHENYLETHANAMINE, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR TREATING ALZHEIMER'S DISEASE (AD), VASCULAR DEMENTIA, DEMENTIA WITH LEWY BODIES (DLB), MIXED DEMENTIA, FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AND PARKINSON'S DISEASE (PD) | Non-Final OA | NLS Pharmaceutics AG |
| 17783671 | COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | Final Rejection | RIJKSUNIVERSITEIT GRONINGEN |
| 17285397 | NUTRITION COMPOSITION | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18253541 | COMPOUNDS AND USES THEREOF | Non-Final OA | Foghorn Therapeutics Inc. |
| 18493773 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Non-Final OA | Arvinas Operations, Inc. |
| 17914545 | PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | Non-Final OA | UPPTHERA |
| 18001034 | COMPOUND FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | Non-Final OA | METRIOPHARM AG |
| 18300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | Non-Final OA | Woolsey Pharmaceuticals, Inc. |
| 17799609 | HETEROCYCLIC GLP-1 AGONISTS | Non-Final OA | Gasherbrum Bio, Inc. |
| 18120318 | PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | Non-Final OA | CHINA PHARMACEUTICAL UNIVERSITY |
| 18011154 | ANTIVIRAL USE OF CALIXARENES | Non-Final OA | CEBINA GmbH |
| 17999001 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Non-Final OA | PATHIOS THERAPEUTICS LIMITED |
| 17922576 | FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS | Non-Final OA | AJK BIOPHARMACEUTICAL, LLC |
| 17764092 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Final Rejection | LENGO THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy